ImaginAb Overview
- Year Founded
-
2007
- Status
-
Private
- Employees
-
13
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$12.8M
- Investors
-
10
ImaginAb General Information
Description
Developer of engineered antibody fragments designed to be used for diagnostic imaging and radioimmunotherapy. The company's fragments are based on a clinical product pipeline that comprises prostate stem cell antigen for prostate, bladder, and pancreatic cancer; J591 prostate-specific membrane antigen for prostate cancer, and T-cell co-receptors for cancer, providing healthcare professionals with new insights into patients' treatment of immuno-oncology therapies.
Contact Information
Website
imaginab.comCorporate Office
- 4500 Park Granada
- Suite 202
- Calabasas, CA 91302
- United States
Corporate Office
- 4500 Park Granada
- Suite 202
- Calabasas, CA 91302
- United States
ImaginAb Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Later Stage VC | 03-Jun-2021 | $12.8M | Completed | Clinical Trials - Phase 2 | ||
| 10. Secondary Transaction - Private | Completed | Clinical Trials - General | ||||
| 9. Debt - PPP | 14-Apr-2020 | Completed | Clinical Trials - General | |||
| 8. Later Stage VC | 08-Oct-2018 | Completed | Clinical Trials - General | |||
| 7. Later Stage VC | 14-Sep-2017 | Completed | Pre-Clinical Trials | |||
| 6. Later Stage VC (Series A3) | 12-Apr-2016 | Completed | Pre-Clinical Trials | |||
| 5. Later Stage VC (Series B) | 08-May-2014 | Completed | Pre-Clinical Trials | |||
| 4. Later Stage VC (Series A) | 26-Mar-2012 | Completed | Pre-Clinical Trials | |||
| 3. Grant | 01-Nov-2011 | $2.3M | Completed | Startup | ||
| 2. Seed Round | Completed | Startup |
ImaginAb Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C-2 | ||||||||
| Series C | ||||||||
| Series B | 5,867,347 | $0.150000 | $0.06 | $0.98 | $0.98 | 1x | $0.98 | 7.95% |
| Series A | 20,021,060 | $0.150000 | $0.03 | $0.49 | $0.49 | 1x | $0.49 | 27.13% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
ImaginAb Comparisons
Industry
Financing
Details
ImaginAb Competitors (73)
One of ImaginAb’s 73 competitors is Adaptimmune Therapeutics, a Formerly VC-backed company based in Abingdon, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| MaveriX Oncology | Venture Capital-Backed | Palo Alto, CA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Cristal Therapeutics | Venture Capital-Backed | Maastricht, Netherlands |
ImaginAb Patents
ImaginAb Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025064446-A1 | Antigen binding constructs | Inactive | 19-Sep-2023 | ||
| WO-2025064435-A1 | Antigen binding constructs directed to integrin αvβ6 | Inactive | 19-Sep-2023 | ||
| WO-2025064435-A8 | Antigen binding constructs directed to integrin αvβ6 | Inactive | 19-Sep-2023 | ||
| US-20250236668-A1 | Antibodies and methods of making and using same | Pending | 08-Jul-2022 | ||
| WO-2024011186-A2 | Antibodies and methods of making and using same | Inactive | 08-Jul-2022 | C07K16/28 |
ImaginAb Signals
ImaginAb Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Norgine Ventures | Lender/Debt Provider | Minority | ||
| Merck & Co. | Corporation | Minority | ||
| Adage Capital Management | Hedge Fund | Minority | ||
| Parker Institute for Cancer Immunotherapy | Corporation | Minority | ||
| Raptor Holdco GP. | Venture Capital | Minority |
ImaginAb FAQs
-
When was ImaginAb founded?
ImaginAb was founded in 2007.
-
Where is ImaginAb headquartered?
ImaginAb is headquartered in Calabasas, CA.
-
What is the size of ImaginAb?
ImaginAb has 13 total employees.
-
What industry is ImaginAb in?
ImaginAb’s primary industry is Drug Discovery.
-
Is ImaginAb a private or public company?
ImaginAb is a Private company.
-
What is the current valuation of ImaginAb?
The current valuation of ImaginAb is .
-
What is ImaginAb’s current revenue?
The current revenue for ImaginAb is .
-
How much funding has ImaginAb raised over time?
ImaginAb has raised $65.1M.
-
Who are ImaginAb’s investors?
Norgine Ventures, Merck & Co., Adage Capital Management, Parker Institute for Cancer Immunotherapy, and Raptor Holdco GP. are 5 of 10 investors who have invested in ImaginAb.
-
Who are ImaginAb’s competitors?
Adaptimmune Therapeutics, MaveriX Oncology, Inovio Pharmaceuticals, Ayala Pharmaceuticals, and Cristal Therapeutics are some of the 73 competitors of ImaginAb.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process